Moreover, analysis using the Tumor Immune Dysfunction and Exclusion algorithm indicated that immune checkpoint blockade therapy might be beneficial for high-risk LADC patients, whose tumor tissues have higher expression levels of PD-L1 and PD-L2 [57]. Here, PDCD1LG2 is linked to neoplasm.